Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Exploring the Demodex Blepharitis Market: Clinical Viewpoints, Pipeline Evaluation, and Market Access Services | Disease Landscape Insights


News provided by

Disease Landscape Insights

11 Sep, 2023, 14:11 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Sept. 11, 2023 /PRNewswire/ -- Eyes are one of the vital sense organs of our body that enables us to see everything presence in and around us. It is crucial for us to take care of this gift. But like other organs, eyes are also subject to numerous disorders. Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids. These mites are also known to be present on hair follicles and human skin. We at Disease Landscape Insights (DLI) aim to assist our clientele in understanding the characteristics of this disease and help them develop cutting edge treatment solutions. Unlocking Insights into Demodex Blepharitis – From Research to Treatment Solutions, Dive Deeper into Managing this Eye Condition.

Elaborating the Causes and Symptoms of this Dreadful Disease:

This devastating ailment is known to affect a significant part of the global population. It predominantly impacts the geriatric individuals aged above 60. According to a data released by NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis. The major factor behind the occurrence of this condition is the overpopulation of Demodex mites on the eyelids. Apart from that, age, weak immune system, poor hygiene, and the presence of certain skin conditions are some of the additional Demodex Blepharitis causes.

Patients affected with Demodex Blepharitis may witness diverse symptoms depending on the severity of this ailment. Some of the commonly occurring symptoms are constant tearing, dry eyes, itchiness, redness, eyelid itching, light sensitivity, blurred vision, and eyelid infections, among others.

In certain cases, this disorder may result in the onset of Chalazion, Meibomian Gland Dysfunction, Ocular Rosacea, and Styes.

Key takeaways:

  • According to NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis.
  • It is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.
  • Major symptoms may include itchiness, inflammation, redness, blurry vision, infection, and light sensitivity, among others.
  • Age, weak immune system, poor hygiene, and the presence of certain skin conditions may also lead to the onset of this ophthalmic ailment.

Price and Market Access

What are the diagnostic solutions for Demodex Blepharitis?

The diagnosis of Demodex blepharitis typically involves a series of eye examination by an eye care professional, such as an ophthalmologist or optometrist. Let us delve into the most common diagnostic procedures-

  • Eyelid Examination-

A comprehensive examination of the eyelids is conducted by eye doctors using a slit lamp microscope. This enables them to identify signs of inflammation, redness, and crusting on the eyelid margins, which are primary indicators of this eye disorder.

  • Meibomian Gland Expression-

By evaluating the expression of meibomian glands, eye doctors can detect this ailment. This is because of the fact that these glands are located in the eyelids and get severely affected by mite infestation.

  • Epilation and Microscope Examination-

In this procedure, eyelashes are plucked and thoroughly observed under a microscope. The presence of demodex eggs, mites, or excreta on the eyelashes can be easily determined through this examination.

  • Demodex Quantification Tests-

These tests involve the counting of the number of Demodex mites per eyelash along with the measurement of their density on the eyelid margins.

Apart from the aforementioned tests, eyelash cellophane tape test, fluorescein staining, and in-vivo confocal microscopy, can also be conducted for the detection of this inflammatory eye disorder.

Treatment Landscape:

The treatment solutions for this ailment typically aim to control the population of the mites while alleviating the symptoms. With widespread R&D activities, numerous treatment solutions in the form of drugs, personal hygiene products, and therapies have emerged over time. Pharma and biotech companies are making extensive efforts in developing effective treatment solutions for Demodex Blepharitis. DLI with its deep dive expertise in the field has been offering a helping hand to these players when it comes to R&D activities, clinical trials, competitive research, launch strategies along with post launch strategies among others.

Several companies and healthcare organizations have successfully developed and launched topical medicines, oral drugs like doxycline, medicated shampoos, eyedrops, and intense pulse light therapy, among others. These products are working wonders in alleviating the symptoms of this devasting ophthalmic disease.

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Psoriasis Disease:

https://www.diseaselandscape.com/requestsample/postid/65 

Effective Demodex Blepharitis Drugs:

Demodex Blepharitis disease burden is increasing at an alarming rate worldwide. Treatment gap identification by medical researchers and pharmaceutical companies have expedited the R&D activities aimed at the development of highly effective drugs in this vertical. These entities are taking assistance from healthcare consultants to understand the regulatory standards which they need to adhere to during the drug development process. Apart from that, it is also crucial for them to get a gist of the drug launch strategies required to be formulated in the long run.

Some of the drugs that have shown immense potential during the clinical trial assessments and have been approved for commercial use are-

  • Metronidazole
  • Azithromycin
  • Ivermectin
  • Doxycycline
  • Ivermectin

Elucidating the Post launch Scenario:

Once a drug receives approval for public use, it is crucial for pharmaceutical companies to strengthen their post launch strategies. It predominantly combines pricing and reimbursement decisions, product portfolio extension, analysis on the overall market access, drug monitoring, additional clinical trials, along with labelling updates. These post-launch services collectively play a pivotal role in achieving therapeutic success while minimizing potential risks.

Our Services: https://www.diseaselandscape.com/services 

Final Words:

Demodex Blepharitis is a dreadful inflammatory eye disorder affected a large number of individuals. The geriatric population is highly susceptible to this ailment due to their weakened immune system. This disorder is predominantly caused by the overpopulation of Demodex eyelid mites. Major symptoms may include itchiness, inflammation, redness, blurry vision, infection, and light sensitivity, among others. Medical researchers along with biotech and pharma companies are collaborating with an aim to develop and commercialize effective treatment solutions for this condition. DiseaseLandscape Insights has been supporting these organizations in their quest to develop highly effective Demodex Blepharitis therapies in the form of drugs and topical medicines.  

Search more about Environmental Diseases @ https://www.diseaselandscape.com/disease/environmental

Related Blogs:

Top Companies Battling Monkeypox: Pioneering Solutions Against the Virus

Unraveling Drug Discovery & Development: Research Insights

Lung Cancer Insights: Causes, Treatment Advancements, and Leading Companies

Strategies to Boost Revenue in Clinical Trials: Overcoming CRO Challenges

Xdemvy: A Breakthrough in Demodex Blepharitis Treatment with Lotilaner

Miebo: Leading the Way in Dry Eye Disease Treatment with Impressive Outcomes

Veozah: Advancing Women's Health with Fezolinetant by Astellas Pharma Inc.

Qalsody: A Revolutionary Breakthrough Treatment by Biogen Inc.

Elfabrio's Pegunigalsidase Alfa-iwxj: Advancing Fabry Disease Cure

The Path to a Successful Drug Launch: A Guide for Pharmaceutical Companies

Zavzpret: Empowering Migraine Sufferers with a Ray of Hope

Optimizing Clinical Trials: Enhancing Ancillary Management

Investor Excellence: Bridging Gaps for Global Impact

Immunotherapy: Confronting Challenges in Cancer Treatment

Managing the Alzheimer's Landscape: Unique Solutions for Market Players

Exploring the Global Market for Monkeypox Disease: A Healthier Future

Illuminating Hope: Overcoming Limits in Lupus Disease

Leading the Way in Psoriasis Care: Innovations in Topical Drug Delivery

Redefining Hemophilia Care: Strategies for Regulatory and Market Access

Breakthrough Against Parkinson's: Exciting Developments in ND0612 Trials

About Disease Landscape:

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.

Contact Us:
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1
Solitaire Business Hub, Viman Nagar
Pune, Maharashtra, 411014
Email: ajay@diseaselandscape.com  
Email : vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs
Case Study: https://www.diseaselandscape.com/casestudies
Pharma consulting Services
Follow Us: LinkedIn | Twitter | Facebook

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.